Novartis Boosts HCV Portfolio With First-in-Class Debiopharm Compound
This article was originally published in The Pink Sheet Daily
Executive SummaryHepatitis C sector heats up as Novartis gains rights to Debiopharm's leading cyclophilin inhibitor
You may also be interested in...
Phase II trial of alisporivir plus ribavirin began after FDA modified its partial clinical hold; previous regimen included peg-interferon.